Atara Biotherapeutics develops immunotherapy treatments for patients with cancer, autoimmune, and viral diseases using off-the-shelf T-cells. Its lead candidate is tabelecleucel, a Phase 3 immunotherapy for the treatment of several types of tumors, including EBV-driven post-transplant lymphoproliferative disease. Atara is also developing next-generation CAR T therapies for patients with various malignancies and has partnerships with research institutions and pharma companies.